<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>19(3)</volume><submitter>Manning L</submitter><funding>The Western Australia Department of Health</funding><pubmed_abstract>There is an urgent need for interventions that improve healing time, prevent amputations and recurrent ulceration in patients with diabetes-related foot wounds. In this randomised, open-label trial, participants were randomised to receive an application of non-cultured autologous skin cells ("spray-on" skin; ReCell) or standard care interventions for large (>6 cm&lt;sup>2&lt;/sup> ), adequately vascularised wounds. The primary outcome was complete healing at 6 months, determined by assessors blinded to the intervention. Forty-nine eligible foot wounds in 45 participants were randomised. An evaluable primary outcome was available for all wounds. The median (interquartile range) wound area at baseline was 11.4 (8.8-17.6) cm&lt;sup>2&lt;/sup> . A total of 32 (65.3%) index wounds were completely healed at</pubmed_abstract><journal>International wound journal</journal><pagination>470-481</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8874115</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Wound healing with "spray-on" autologous skin grafting (ReCell) compared with standard care in patients with large diabetes-related foot wounds: an open-label randomised controlled trial.</pubmed_title><pmcid>PMC8874115</pmcid><pubmed_authors>Norman PE</pubmed_authors><pubmed_authors>Davis WA</pubmed_authors><pubmed_authors>Hiew J</pubmed_authors><pubmed_authors>Baba M</pubmed_authors><pubmed_authors>Hamilton EJ</pubmed_authors><pubmed_authors>Ferreira IB</pubmed_authors><pubmed_authors>Carville K</pubmed_authors><pubmed_authors>Gittings P</pubmed_authors><pubmed_authors>Wood F</pubmed_authors><pubmed_authors>Raby E</pubmed_authors><pubmed_authors>Ritter JC</pubmed_authors><pubmed_authors>Ryan E</pubmed_authors><pubmed_authors>Manning L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Wound healing with "spray-on" autologous skin grafting (ReCell) compared with standard care in patients with large diabetes-related foot wounds: an open-label randomised controlled trial.</name><description>There is an urgent need for interventions that improve healing time, prevent amputations and recurrent ulceration in patients with diabetes-related foot wounds. In this randomised, open-label trial, participants were randomised to receive an application of non-cultured autologous skin cells ("spray-on" skin; ReCell) or standard care interventions for large (>6 cm&lt;sup>2&lt;/sup> ), adequately vascularised wounds. The primary outcome was complete healing at 6 months, determined by assessors blinded to the intervention. Forty-nine eligible foot wounds in 45 participants were randomised. An evaluable primary outcome was available for all wounds. The median (interquartile range) wound area at baseline was 11.4 (8.8-17.6) cm&lt;sup>2&lt;/sup> . A total of 32 (65.3%) index wounds were completely healed at</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-04-04T12:43:38.536Z</modification><creation>2025-04-04T12:43:38.536Z</creation></dates><accession>S-EPMC8874115</accession><cross_references><pubmed>34156758</pubmed><doi>10.1111/iwj.13646</doi></cross_references></HashMap>